| Recruiting | MTS109 in Patients With Refractory Autoimmune Diseases NCT07526350 | Shanghai Changzheng Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement NCT07373262 | University Hospital, Toulouse | Phase 3 |
| Not Yet Recruiting | YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases NCT07439029 | Children's Hospital of Fudan University | Phase 1 |
| Not Yet Recruiting | Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Case NCT07451847 | Assistance Publique - Hôpitaux de Paris | Phase 4 |
| Recruiting | PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated Vasculitis NCT07258524 | University of Edinburgh | — |
| Recruiting | Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders NCT07089121 | Cartesian Therapeutics | Phase 1 / Phase 2 |
| Recruiting | CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases NCT07315087 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Recruiting | BDB-001 Phase III Trial in ANCA-Associated Vasculitis NCT07168161 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 3 |
| Not Yet Recruiting | SGLT-2 Inhibitors on Albuminuria in Chronic Kidney Disease Patients With Lupus Nephritis and ANCA- Associated NCT07035834 | Federico II University | Phase 4 |
| Not Yet Recruiting | The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cyto NCT07033299 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Recruiting | Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases NCT06828042 | Peking University Third Hospital | Phase 1 / Phase 2 |
| Recruiting | A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases NCT06980597 | Beijing GoBroad Hospital | Phase 1 |
| Recruiting | Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy NCT07150000 | University of Bonn | — |
| Recruiting | Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA NCT06868290 | Novartis Pharmaceuticals | Phase 2 |
| Not Yet Recruiting | Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of R NCT06821659 | Peking University Third Hospital | Phase 1 / Phase 2 |
| Recruiting | CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases NCT06941129 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Recruiting | Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases NCT06614270 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Recruiting | Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases NCT06775912 | Nanjing Bioheng Biotech Co., Ltd. | EARLY_Phase 1 |
| Recruiting | AYLo - AutoimmunitY and Loss of y NCT06696027 | University of Bonn | — |
| Recruiting | Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis NCT06611696 | Chiba University | Phase 4 |
| Enrolling By Invitation | A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease NCT06375993 | Adicet Therapeutics | Phase 1 |
| Recruiting | Rare AutoImmune SElf-management Programme Development NCT06642870 | University of the West of England | — |
| Terminated | IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy NCT06462144 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | EARLY_Phase 1 |
| Completed | The ANCA Vasculitis Questionnaire (AAV-PRO©) NCT02507024 | University of Pennsylvania | — |